<p>Innovent Biologics Inc. has announced the initiation of a pivotal Phase 3 clinical study, HeriCare-Breast01, evaluating IBI354—a HER2 monoclonal antibody-camptothecin derivative conjugate (HER2 ADC)—as a first-line treatment for patients with unresectable locally advanced or metastatic HER2-positive breast cancer. The first participant has been successfully dosed in this study in China. IBI354 is also being investigated in another ongoing pivotal Phase 3 trial, HeriCare-Ovarian01. Early-stage studies have demonstrated a favorable safety and efficacy profile for IBI354, but the results of the current Phase 3 trial have not yet been presented and are anticipated in the future. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN85790) on February 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

588860

159849

516820

<p>Innovent Biologics Inc. has initiated a Phase 3 clinical trial, HeriCare-Breast01, for IBI354, a HER2 ADC, as a first-line treatment for advanced HER2-positive breast cancer. The first patient has been dosed in China. IBI354 is also part of another Phase 3 trial, HeriCare-Ovarian01. Early studies show promising safety and efficacy, but results from the current trial are pending.</p>

PUBT

ICBCCS SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

ChinaAMC CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund CSI Biotechnology Theme ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Penghua SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Guotai SSE STAR Brand Name Drug ETF

E Fund CSI 300 Health Care ETF

Innovent Biologics Doses First Patient in Phase 3 Trial of Novel HER2 ADC for Advanced Breast Cancer